Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Sagimet Biosciences Inc. - Series A Common Stock (NQ:SGMT)

9.410 -0.140 (-1.47%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 18, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 487,598
Open 9.650
Bid (Size) 9.010 (1)
Ask (Size) 9.520 (2)
Prev. Close 9.550
Today's Range 9.150 - 9.740
52wk Range 1.730 - 10.43
Shares Outstanding 30,674,855
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Here are the top movers in Thursday's session.
Curious to know what's happening on the US markets one hour before the close of the markets on Thursday? Join us as we explore the top gainers and losers in today's session. 
Via Chartmill
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga

Performance

YTD
+109.6%
+109.6%
1 Month
+36.8%
+36.8%
3 Month
+325.8%
+325.8%
6 Month
+120.4%
+120.4%
1 Year
+176.8%
+176.8%

More News

Read More
Sagimet Biosciences to Host Virtual KOL Event, “A New Mechanism of Action in Treating Acne: Update on Positive Phase 3 Denifanstat Trial for the Treatment of Moderate to Severe Acne” on June 16, 2025
From Sagimet Biosciences Inc.
Via GlobeNewswire
These stocks are moving in today's pre-market session
Via Chartmill
Sagimet's Partner Achieves Positive Results With Oral Acne Drug In Phase 3 Trial In China, Stock Jumps
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Sagimet Biosciences Announces Positive Phase 3 Results for Denifanstat for the Treatment of Moderate-to-Severe Acne from Partner Ascletis
From Sagimet Biosciences Inc.
Via GlobeNewswire
Sagimet Biosciences to Host Virtual KOL Event, “Evaluating the Synergistic Potential of a Combination of Denifanstat and Resmetirom for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH)” on May 29, 2025
From Sagimet Biosciences Inc.
Via GlobeNewswire
Sagimet Biosciences Reports First Quarter 2025 Financial Results and Provides Corporate Updates
From Sagimet Biosciences Inc.
Via GlobeNewswire
Sagimet Biosciences Announces Upcoming Presentations at EASL Congress 2025
From Sagimet Biosciences Inc.
Via GlobeNewswire
The market is filled with gapping stocks in Monday's session.
Via Chartmill
Sagimet Biosciences Reports Full Year 2024 Financial Results and Provides Corporate Updates
From Sagimet Biosciences Inc.
Via GlobeNewswire
Sagimet Biosciences Announces Clearance of IND for FASN Inhibitor TVB-3567, to be Developed for the Treatment of Acne
From Sagimet Biosciences Inc.
Via GlobeNewswire
Sagimet Biosciences Announces Oral Presentation at the MASH Pathogenesis and Therapeutic Approaches Keystone Symposium
From Sagimet Biosciences Inc.
Via GlobeNewswire
This Vital Farms Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
Via Benzinga
Sagimet Biosciences Announces Oral Presentation at the 9th Annual MASH-TAG 2025 Conference
From Sagimet Biosciences Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Why Edgewise Therapeutics Shares Are Trading Higher By Over 26%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Sagimet Biosciences to Participate in the Piper Sandler 36th Annual Healthcare Conference
From Sagimet Biosciences Inc.
Via GlobeNewswire
Sagimet Biosciences Presents Clinical Denifanstat and Preclinical FASN Inhibitor Data at AASLD - The Liver Meeting® 2024
From Sagimet Biosciences Inc.
Via GlobeNewswire
Sagimet Biosciences Reports Third Quarter 2024 Financial Results and Provides Corporate Updates
From Sagimet Biosciences Inc.
Via GlobeNewswire
This Nvidia Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
Via Benzinga
Sagimet Biosciences to Participate in the UBS Global Healthcare Conference
From Sagimet Biosciences Inc.
Via GlobeNewswire
Madrigal Catapults After Novo's Wegovy Proves It's No 'Silver Bullet' In MASH
Via Investor's Business Daily
Sagimet Biosciences Announces Successful Completion of End-of-Phase 2 Interactions with FDA on the Development of Denifanstat for MASH; Phase 3 Program Initiation Expected by End of 2024
From Sagimet Biosciences Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Sagimet Biosciences Inc. - Series A Common Stock publicly traded?
Yes, Sagimet Biosciences Inc. - Series A Common Stock is publicly traded.
What exchange does Sagimet Biosciences Inc. - Series A Common Stock trade on?
Sagimet Biosciences Inc. - Series A Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Sagimet Biosciences Inc. - Series A Common Stock?
The ticker symbol for Sagimet Biosciences Inc. - Series A Common Stock is SGMT on the Nasdaq Stock Market
What is the current price of Sagimet Biosciences Inc. - Series A Common Stock?
The current price of Sagimet Biosciences Inc. - Series A Common Stock is 9.410
When was Sagimet Biosciences Inc. - Series A Common Stock last traded?
The last trade of Sagimet Biosciences Inc. - Series A Common Stock was at 07/18/25 04:00 PM ET
What is the market capitalization of Sagimet Biosciences Inc. - Series A Common Stock?
The market capitalization of Sagimet Biosciences Inc. - Series A Common Stock is 288.65M
How many shares of Sagimet Biosciences Inc. - Series A Common Stock are outstanding?
Sagimet Biosciences Inc. - Series A Common Stock has 289M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.